Codexis heads into its third-quarter report with an unusual mix of operating progress and investor skepticism. Last quarter management raised its gross margin outlook, stretched its cash runway into 2028 and said its lead manufacturing partner had moved into commercial contract talks. Since then the stock has fallen 27.5%, trailing the S&P 500 by nearly 25 points. The gap between that improving narrative and a falling share price makes this report a test of whether revenue can finally catch up with management's confidence.

The Street expects a loss of $0.09 a share on revenue of $18.5 million, after the company reported Q2 revenue of $14.9 million. That revenue figure would more than double the $8.6 million reported a year ago, and the expected loss would be well below last year's $0.22 per share. The comparison flatters, though, because the year-ago quarter was weak. The more useful benchmark is sequential. Revenue was roughly flat across the first two quarters at about $15 million each, totaling around $30 million. Management has repeatedly reaffirmed full-year guidance of $72 million to $76 million, which implies roughly $42 million to $46 million in the second half. Consensus of $74.45 million sits comfortably inside that range, slightly above the midpoint, and the third-quarter estimate leaves something near $26 million to be delivered in the fourth quarter. In other words, even a quarter in line with the $18.5 million estimate would keep the hardest work ahead.

That back-half weighting is the central risk management itself flagged. The CFO described the base biocatalysis business as lumpy and hard to predict, and management's answer on the second-half ramp amounted to asking investors to wait and see. Supporting the case are four new commercial approvals in 2026 plus a label expansion, lifting the portfolio to 14 products, and a reframed outlook for high-single-digit growth in the base business over five to seven years. A clean step up in Q3, ideally with commentary tying it to those new products rather than one-off orders, would validate the return-to-growth story. A shortfall, or a revenue figure propped up by timing, would deepen doubts about whether the full-year range is realistic.

Margins offer a second checkpoint. Gross margin climbed to 73% in Q2 from 71% in Q1 and 64% for all of 2025, prompting a raised full-year target in the high 60s. Holding near the low 70s would support the view that product mix is structurally improving, while a slide back toward 2025 levels would undercut one of last quarter's few hard upgrades. Cash also matters. Reserves fell from $78.2 million at year-end to $54.9 million in June before a $25 million net equity raise, so the burn rate this quarter will show whether the 2028 runway claim has real cushion, particularly with roughly $25 million earmarked for a GMP facility.

The longer-term catalyst is the siRNA manufacturing platform. Investors should look for news that the lead contract manufacturer has signed a long-term commercial agreement, along with progress on scale-up toward half-kilogram batches by year-end and on the facility permit. A signed contract would turn a promise into a revenue pathway; continued negotiation without resolution would keep it speculative.

Sentiment has improved from the prior quarter but remains bearish, and the stock at $1.08 sits barely above its post-earnings low of $1.04 and far below its 200-day average of $1.81. Expectations for the share price are low, but expectations for the business are not. The report ultimately hinges on one question: does third-quarter revenue show the second-half ramp is genuinely underway, or does the burden shift even more heavily onto the fourth quarter?